<code id='5F8EBC1A35'></code><style id='5F8EBC1A35'></style>
    • <acronym id='5F8EBC1A35'></acronym>
      <center id='5F8EBC1A35'><center id='5F8EBC1A35'><tfoot id='5F8EBC1A35'></tfoot></center><abbr id='5F8EBC1A35'><dir id='5F8EBC1A35'><tfoot id='5F8EBC1A35'></tfoot><noframes id='5F8EBC1A35'>

    • <optgroup id='5F8EBC1A35'><strike id='5F8EBC1A35'><sup id='5F8EBC1A35'></sup></strike><code id='5F8EBC1A35'></code></optgroup>
        1. <b id='5F8EBC1A35'><label id='5F8EBC1A35'><select id='5F8EBC1A35'><dt id='5F8EBC1A35'><span id='5F8EBC1A35'></span></dt></select></label></b><u id='5F8EBC1A35'></u>
          <i id='5F8EBC1A35'><strike id='5F8EBC1A35'><tt id='5F8EBC1A35'><pre id='5F8EBC1A35'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:9
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Some dementia cases could be undiagnosed liver disease
          Some dementia cases could be undiagnosed liver disease

          AdobeThedescentintodementiacanfeelliketraversingaminefield,comingacrossnewsymptomswithoutthehopeofac

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Medicare drug price negotiation’s day in court

          AdobeYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-weeklynewsletteraboutthepoliticsandpolicy